KR101131309B1 - Ｅｇｆｒ 경로를 표적화하는 약물로 치료하기 위한 두경부암 환자의 선별 - Google Patents

Ｅｇｆｒ 경로를 표적화하는 약물로 치료하기 위한 두경부암 환자의 선별 Download PDF

Info

Publication number
KR101131309B1
KR101131309B1 KR1020107019382A KR20107019382A KR101131309B1 KR 101131309 B1 KR101131309 B1 KR 101131309B1 KR 1020107019382 A KR1020107019382 A KR 1020107019382A KR 20107019382 A KR20107019382 A KR 20107019382A KR 101131309 B1 KR101131309 B1 KR 101131309B1
Authority
KR
South Korea
Prior art keywords
spectrum
treatment
patient
benefit
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107019382A
Other languages
English (en)
Korean (ko)
Other versions
KR20110047171A (ko
Inventor
하인리히 뢰더
맥심 차이핀
줄리아 그리고리에바
Original Assignee
바이오디식스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오디식스, 인크. filed Critical 바이오디식스, 인크.
Publication of KR20110047171A publication Critical patent/KR20110047171A/ko
Application granted granted Critical
Publication of KR101131309B1 publication Critical patent/KR101131309B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Software Systems (AREA)
  • Computing Systems (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Computation (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
KR1020107019382A 2009-01-20 2009-11-20 Ｅｇｆｒ 경로를 표적화하는 약물로 치료하기 위한 두경부암 환자의 선별 Expired - Fee Related KR101131309B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/321,393 US7867775B2 (en) 2006-03-31 2009-01-20 Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US12/321,393 2009-01-20
PCT/US2009/006269 WO2010085235A1 (en) 2009-01-20 2009-11-20 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway

Publications (2)

Publication Number Publication Date
KR20110047171A KR20110047171A (ko) 2011-05-06
KR101131309B1 true KR101131309B1 (ko) 2012-04-02

Family

ID=41559566

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107019382A Expired - Fee Related KR101131309B1 (ko) 2009-01-20 2009-11-20 Ｅｇｆｒ 경로를 표적화하는 약물로 치료하기 위한 두경부암 환자의 선별

Country Status (11)

Country Link
US (1) US7867775B2 (https=)
EP (1) EP2247954B1 (https=)
JP (1) JP5025802B2 (https=)
KR (1) KR101131309B1 (https=)
AT (1) ATE516503T1 (https=)
AU (1) AU2009338174B2 (https=)
CA (1) CA2718113A1 (https=)
ES (1) ES2368784T3 (https=)
IL (1) IL211943A (https=)
TW (1) TWI368737B (https=)
WO (1) WO2010085235A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
CN102770760A (zh) * 2010-02-24 2012-11-07 佰欧迪塞克斯公司 利用质谱分析选择施用治疗剂的癌症患者
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
AU2013287262A1 (en) 2012-07-05 2015-02-26 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
WO2017011439A1 (en) 2015-07-13 2017-01-19 Biodesix, Inc. Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods
US11710539B2 (en) 2016-02-01 2023-07-25 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
WO2017176423A1 (en) 2016-04-08 2017-10-12 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
WO2018129301A1 (en) 2017-01-05 2018-07-12 Biodesix, Inc. Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
WO2019032525A1 (en) 2017-08-07 2019-02-14 Genecentric Therapeutics, Inc. PROCESS FOR SUBTYPING EPIDERMOID CARCINOMA OF HEAD AND NECK
WO2019046585A1 (en) * 2017-08-30 2019-03-07 Genecentric Therapeutics, Inc. ANALYSIS OF GENE EXPRESSION SUB-TYPES OF EPIDERMOID CARCINOMA OF HEAD AND NECK FOR TREATMENT MANAGEMENT
US12094587B2 (en) 2018-03-29 2024-09-17 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
US20230386662A1 (en) * 2020-10-19 2023-11-30 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Rapid and direct identification and determination of urine bacterial susceptibility to antibiotics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US20070231921A1 (en) * 2006-03-31 2007-10-04 Heinrich Roder Method and system for determining whether a drug will be effective on a patient with a disease
US20090171872A1 (en) * 2006-03-31 2009-07-02 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101107765B1 (ko) 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
US20050267689A1 (en) * 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
WO2005010492A2 (en) 2003-07-17 2005-02-03 Yale University Classification of disease states using mass spectrometry data
US20090204334A1 (en) 2004-03-30 2009-08-13 Eastern Virginia Medical School Lung cancer biomarkers
ES2425749T3 (es) * 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
US20060029574A1 (en) * 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US20070231921A1 (en) * 2006-03-31 2007-10-04 Heinrich Roder Method and system for determining whether a drug will be effective on a patient with a disease
US20090171872A1 (en) * 2006-03-31 2009-07-02 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

Also Published As

Publication number Publication date
TW201028688A (en) 2010-08-01
EP2247954A1 (en) 2010-11-10
CA2718113A1 (en) 2010-07-29
US20090171872A1 (en) 2009-07-02
AU2009338174A1 (en) 2010-07-29
AU2009338174B2 (en) 2012-02-02
IL211943A0 (en) 2011-06-30
ES2368784T3 (es) 2011-11-22
IL211943A (en) 2014-01-30
US7867775B2 (en) 2011-01-11
KR20110047171A (ko) 2011-05-06
JP2011513728A (ja) 2011-04-28
WO2010085235A1 (en) 2010-07-29
JP5025802B2 (ja) 2012-09-12
HK1148073A1 (en) 2011-08-26
ATE516503T1 (de) 2011-07-15
EP2247954B1 (en) 2011-07-13
TWI368737B (en) 2012-07-21

Similar Documents

Publication Publication Date Title
KR101131309B1 (ko) Ｅｇｆｒ 경로를 표적화하는 약물로 치료하기 위한 두경부암 환자의 선별
KR101131231B1 (ko) Ｅｇｆｒ 경로를 표적화하는 약물로 치료하기 위한 대장암 환자의 선별
US7858389B2 (en) Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
Washam et al. Identification of PTHrP (12-48) as a plasma biomarker associated with breast cancer bone metastasis
US8586379B2 (en) Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
AU2012209515B2 (en) Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy
JP2019049557A (ja) 癌療法を示すためのｓｒｍアッセイ
WO2019010429A1 (en) METHODS OF DIAGNOSING PANCREATIC CANCER
CN106164676A (zh) 针对pd‑l1的srm测定
CN110891579A (zh) 用于优化癌症治疗方案的slfn11蛋白的量化
Dienemann et al. Reliable entity subtyping in non-small cell lung cancer by MALDI imaging mass spectrometry on formalin-fixed paraffin-embedded tissue specimens
HK1148073B (en) Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway
HK1156696B (en) Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway
JP2019529896A (ja) チューブリンベータ−３鎖（ｔｕｂｂ３）タンパク質に対するｓｒｍ／ｍｒｍアッセイ

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A302 Request for accelerated examination
PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

FPAY Annual fee payment

Payment date: 20150309

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160309

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170322

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170322

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000